SCHEDULE 13D/A: Organogenesis Holdings: Key Insiders Update Significant Shareholdings in Latest SEC Filing
Beneficial Ownership Amendment
A group of significant shareholders, including Alan A. Ades and Albert Erani, have filed Amendment No. 9 to their Schedule 13D, detailing updated beneficial ownership percentages and recent share transfers, notably a large gift for estate planning purposes.
Summary
- This document is Amendment No. 9 to the Schedule 13D filing for Organogenesis Holdings Inc., updating beneficial ownership information for a group of reporting persons.
- The beneficial ownership percentages are based on 125,725,796 Class A Common Shares outstanding as of December 11, 2024.
- As of January 9, 2025, Alan A. Ades beneficially owns 22,319,836 shares, representing approximately 17.8% of the outstanding shares.
- Albert Erani beneficially owns 17,920,498 shares, representing approximately 14.3% of the outstanding shares.
- Glenn H. Nussdorf beneficially owns 11,912,841 shares, representing approximately 9.5% of the outstanding shares.
- Dennis Erani beneficially owns 10,043,701 shares, representing approximately 8.0% of the outstanding shares.
- Josette Ades, spouse of Alan A. Ades, beneficially owns 8,112,497 shares, representing approximately 6.5% of the outstanding shares.
- On January 9, 2025, Alan A. Ades transferred 6,401,945 shares to Josette Ades as a gift for no consideration, primarily for estate planning purposes.
Sentiment
Score: 5
Explanation: The document is a factual update on beneficial ownership and share transfers, primarily for estate planning, and does not contain information that would inherently indicate positive or negative sentiment regarding the company's operational or financial performance.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership changes by a significant shareholder group and does not provide broader industry context or trends. It primarily reflects internal estate planning and share management within the controlling shareholder group of Organogenesis Holdings Inc.
Related Party Transactions
- On January 9, 2025, Alan A. Ades transferred 6,401,945 shares to Josette Ades, his spouse, as a gift for no consideration for estate planning purposes. This is referred to as the 'January 2025 Ades Transfer'.
Stakeholder Impact
- Shareholders: The filing provides transparency regarding the significant ownership stakes held by a key group of individuals and entities, including recent transfers within this group, which can influence perceptions of control and stability.
Key Dates
| Date | Description |
|---|---|
| 2018-12-20 | Original Schedule 13D filing date. |
| 2019-11-27 | Amendment No. 1 to Schedule 13D filed. |
| 2020-11-19 | Amendment No. 2 to Schedule 13D filed. |
| 2021-05-11 | Amendment No. 3 to Schedule 13D filed. |
| 2021-06-01 | Amendment No. 4 to Schedule 13D filed. |
| 2021-12-17 | Amendment No. 5 to Schedule 13D filed. |
| 2021-12-30 | Amendment No. 6 to Schedule 13D filed. |
| 2024-11-12 | Date of the 'Repurchase' transaction as defined in Amendment No. 7. |
| 2024-11-14 | Amendment No. 7 to Schedule 13D filed. |
| 2024-11-27 | Date of the 'GN Trust Repurchase' transaction as defined in Amendment No. 8. |
| 2024-12-11 | Date on which 125,725,796 shares were reported as outstanding in the Issuer's Form S-3. |
| 2024-12-19 | Date the Registration Statement on Form S-3 was filed by the Issuer. |
| 2024-12-31 | Date of the 'Ades Transfer' transaction as defined in Amendment No. 8. |
| 2025-01-03 | Amendment No. 8 to Schedule 13D filed. |
| 2025-01-09 | Date of the 'January 2025 Ades Transfer' (gift of 6,401,945 shares from Alan A. Ades to Josette Ades) and the effective date for reported share numbers. |
| 2025-01-13 | Signature date for the current Amendment No. 9 filing. |
Keywords
Organogenesis Holdings Inc., Schedule 13D, Beneficial Ownership, Insider Holdings, Share Transfer, Estate Planning, Class A Common Stock, SEC Filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.